Skip to ContentSkip to Navigation
About us Practical matters How to find us prof. dr. H.J. (Hiddo) Lambers Heerspink


Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial

Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes

Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials

Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease

Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps

Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study

Impact of age on the predictive value of NT-proBNP in patients with diabetes mellitus stabilised after an acute coronary syndrome

Impact of Using the Race-Free 2021 CKD-EPI Creatinine Equation on Treatment Effects on GFR-Based End Points in Clinical Trials

Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD

Read more


Zibotentan, Dapagliflozin Combo Further Reduces Albuminuria in CKD

New Hope for Treating Chronic Kidney Disease in Type 1 Diabetes

First-in-class treatment delivers major advance for incurable kidney disease

George Institute for Global Health: First-In-Class Treatment Delivers Major Advance for Incurable Kidney Disease

First-in-Class Treatment Brings Major Breakthrough for Incurable Kidney Disease

First-in-class treatment delivers major advance for incurable kidney disease

Diabetes drug can slow kidney function decline, study finds

La dapagliflozina no reduce los riesgos en los pacientes hospitalizados con COVID-19

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

Read more